To ask the Secretary of State for Health and Social Care, whether his Department holds any list of patients who have been identified as immunocompromised and are eligible for new covid-19 treatments first announced in December 2021; and whether such a list includes the addresses of those patients.
This answer is the replacement for a previous holding answer.
21 March 2022
The Department commissioned an independent expert group to identify clinically eligible patient cohorts most likely to progress towards developing severe COVID-19. These cohorts form part of an evidence-based clinical policy for the treatment of COVID-19, agreed by the United Kingdom Chief Medical Officers. The treatments available include the monoclonal antibody therapy sotrovimab, as well as the oral antiviral treatments molnupiravir and nirmatrelvir + ritonavir.
The Department does not hold a list of these patients, nor any identifiable personal information.